Drug Type Monoclonal antibody |
Synonyms + [1] |
Target |
Mechanism IL-4Rα inhibitors(Interleukin-4 receptor subunit alpha inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization Qyuns Therapeutics Co., Ltd.Startup |
Active Organization Qyuns Therapeutics Co., Ltd.Startup |
Inactive Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
RegulationBreakthrough Therapy (CN) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
prurigo nodularis | Phase 3 | CN | Qyuns Therapeutics Co., Ltd.Startup | 22 May 2024 |
Moderate Atopic Dermatitis | Phase 3 | CN | Qyuns Therapeutics Co., Ltd.Startup | 28 Apr 2024 |
Severe Atopic Dermatitis | Phase 3 | CN | Qyuns Therapeutics Co., Ltd.Startup | 28 Apr 2024 |
Chronic rhinosinusitis with nasal polyps | Phase 2 | CN | Qyuns Therapeutics Co., Ltd.Startup | 03 Mar 2023 |
Pulmonary Disease, Chronic Obstructive | IND Approval | CN | Qyuns Therapeutics Co., Ltd.Startup | 15 Sep 2023 |
Asthma | IND Approval | CN | Qyuns Therapeutics Co., Ltd.Startup | 22 Feb 2022 |
Chronic Urticaria | IND Approval | CN | Qyuns Therapeutics Co., Ltd.Startup | 27 Jan 2022 |